Skip to main content
. 2013 Jan 5;15(1):49–57. doi: 10.5812/ircmj.4322

Table 2. Patient Outcomes (n = 29).

No. of Patients Percentage (%) Median ( ± SD), range
KPS at last follow-up 95.52 ± 10.2 (80 - 100)
Tumor Volume at Final Follow-up
Increase/Stable or decrease 6/23 21/79
Survival
Overall survival(OS) 135 (76 – 194) months
Progression free survival(PFS) 96 (1 - 199) months
Cause of death
Neurological death 3 10
Systemic death 12 41
Information missing 3 10
Living patients 11 39